ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 457

Serum Myostatin in Patients with Rheumatoid Arthritis and Its Correlations with Body Compositions and the Disease Activity

Yoko Wada1, Masanori Sudo 2, Daisuke Kobayashi 2, Takeshi Kuroda 3 and Masaaki Nakano 4, 1Niigata Rinko Hospital, Niigata, Niigata, Japan, 2Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Niigata, Japan, 3Health administration office, Niigata University, Niigata, Niigata, Japan, 4School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Niigata, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: cachexia and myostatin, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Altered body composition is a common feature of patients with rheumatoid arthritis (RA), up to two-thirds of affected patients showing loss of muscle mass and strength and a concomitant increase in fat mass, so-called “rheumatoid cachexia”. Despite great advances in the treatment of RA, such as biological agents and small-molecule compounds, rheumatoid cachexia persists even after joint inflammation has improved. Myostatin, a member of the transforming growth factor-beta superfamily, is a potent negative regulator of skeletal muscle growth and its inactivation can induce skeletal muscle hypertrophy, whereas its overexpression or systemic administration causes muscle atrophy. As it enhances proteolysis and inhibits protein synthesis in skeletal muscle, it has generated considerable interest as a potential regulator of cachexic status in patients with conditions such as cancers, cardiac failure, and HIV infection. In this study, we investigated the possible role of myostatin in body composition alteration in patients with RA.

Methods: This was a cross-sectional study. Ninety-six RA patients who visited Niigata University Hospital between April and June 2017 were recruited. Body composition in each subject was measured by bioelectrical impedance analysis with a tetrapolar impedance meter (InBody S-10, InBody Japan Inc., Tokyo, Japan). The serum myostatin level was measured by enzyme-linked immunosorbent assay with a commercially available kit (Quantikine ELISA GDF-8/Myostatin Immunoassay, R&D Systems, MN, USA). Patients’ laboratory findings and disease activities were also measured, and the correlations between the titer of serum myostatin and these factors were analyzed by Spearman’s correlation coefficient and stepwise multiple regression. In addition, 70 female patients from the cohort were divided into two groups according to their fat-free mass index (FFMI) (low FFMI group (FFMI< 13.82, n=20) and normal FFMI group (n=50)), and their clinical findings and serum myostatin levels were compared by Mann-Whitney U test. Differences at p < 0.05 were considered to be statistically significant.

Results: Spearman’s correlation coefficient analysis showed that the serum myostatin level was positively correlated with skeletal muscle mass index and FFMI, and negatively correlated with percentage body fat (%BF), fat mass index (FMI), the swollen joint count, ESR, and DAS28(4)-ESR. Stepwise multiple regression analysis selected FFMI as a positive independent variable (rho=0.3620, p=0.00019) and DAS28(4)-ESR as a negative independent variable (rho=-0.2298, p=0.0154) against the serum myostatin level, respectively. In these 70 female patients, %BF and FMI/FFMI ratio were significantly higher in the low FFMI group than in the normal FFMI group.

Conclusion: The serum myostatin level was significantly correlated with body composition and disease activity in patients with RA. Patients with a lower level of myostatin showed a tendency to have decreased skeletal muscle and increased body fat, suggesting that serum myostatin could be a possible biomarker of rheumatoid cachexia.


Disclosure: Y. Wada, None; M. Sudo, None; D. Kobayashi, None; T. Kuroda, None; M. Nakano, None.

To cite this abstract in AMA style:

Wada Y, Sudo M, Kobayashi D, Kuroda T, Nakano M. Serum Myostatin in Patients with Rheumatoid Arthritis and Its Correlations with Body Compositions and the Disease Activity [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/serum-myostatin-in-patients-with-rheumatoid-arthritis-and-its-correlations-with-body-compositions-and-the-disease-activity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-myostatin-in-patients-with-rheumatoid-arthritis-and-its-correlations-with-body-compositions-and-the-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology